MedWatch

NICE CEO announces new approach to prioritization

The British drug pricing agency NICE is working on new guidelines for how to evaluate new products in a socioeconomic context. But it comes with the risk of an increase in healthcare inequality, the agency’s CEO warns in an interview with Medwatch.

Should healthcare bodies asses new drugs and medical equipment based on the effect and isolated costs of the products? Or should they take secondary effects, such as the number of days a patient does not have to spend in a costly hospital bed, into consideration as well? Or the value a depressive individual could give back to society, if the proper medicine gets that person off of government benefits?

The life science industry has been a long time advocate of the world’s healthcare bodies adapting a more holistic outlook on healthcare expenditure, and public bodies are beginning to take notice and adopt this type of thinking.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP anbefaler coronapille fra Pfizer

Pfizer har fået en positiv anbefaling fra CHMP, der anbefaler at tabletbehandlingen Paxlovid godkendes til behandling af covid-19. I Danmark er midlet dog allerede taget i brug.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier